Cognitive Training for Fragile X Syndrome
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 8 - 18 |
| Updated: | 6/29/2018 |
| Start Date: | January 2013 |
| End Date: | April 2019 |
| Contact: | David R Hessl, PhD |
| Email: | drhessl@ucdavis.edu |
| Phone: | 916-703-0249 |
Individuals with fragile X syndrome (FXS) demonstrate profound executive function deficits
that interfere with learning, socialization and emotion regulation. Extensive research
focused on the animal models of FXS show that targeted pharmacological agents can normalize
synaptic connectivity and reverse cognitive and behavioral deficits. This translational work
has led to multiple national and international controlled trials in humans with FXS now
underway. However, in contrast to the heavy focus on medication treatments, there have been
no controlled trials to empirically-validate cognitive or behavioral interventions for FXS.
The proposed study, the first non-pharmacological controlled trial for FXS, will evaluate the
efficacy of Cogmed, a cognitive training program proven to enhance working memory and
executive/frontal function in a variety of clinical populations. Demonstration of effective
Cogmed training for FXS would represent a major advance in the field, one that may also
generalize to other forms of intellectual disability. Furthermore, it is critical to
determine whether the targeted pharmacological treatments can accelerate learning and
cognitive development. Thus, the validation of Cogmed for FXS will provide a paradigm for
testing hypotheses focused on combined efficacy of medication and cognitive training.
that interfere with learning, socialization and emotion regulation. Extensive research
focused on the animal models of FXS show that targeted pharmacological agents can normalize
synaptic connectivity and reverse cognitive and behavioral deficits. This translational work
has led to multiple national and international controlled trials in humans with FXS now
underway. However, in contrast to the heavy focus on medication treatments, there have been
no controlled trials to empirically-validate cognitive or behavioral interventions for FXS.
The proposed study, the first non-pharmacological controlled trial for FXS, will evaluate the
efficacy of Cogmed, a cognitive training program proven to enhance working memory and
executive/frontal function in a variety of clinical populations. Demonstration of effective
Cogmed training for FXS would represent a major advance in the field, one that may also
generalize to other forms of intellectual disability. Furthermore, it is critical to
determine whether the targeted pharmacological treatments can accelerate learning and
cognitive development. Thus, the validation of Cogmed for FXS will provide a paradigm for
testing hypotheses focused on combined efficacy of medication and cognitive training.
Inclusion Criteria:
- fragile X full mutation
- normal or corrected vision
- English or Spanish speaking
- ability to pass three-span items following completion of a Cogmed training session at
baseline
- parental agreement to maintain adherence to the training schedule and to not alter
other treatments during the study unless medically necessary
Exclusion Criteria:
- previous Cogmed training
- significant medical problems that would interfere with the study or significant brain
trauma
We found this trial at
1
site
Sacramento, California 95817
Principal Investigator: David Hessl, PhD
Phone: 916-703-0202
Click here to add this to my saved trials
